Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

7 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-10-14

Study Completion Date

2018-08-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Despite the implementation of modern public health interventions, 1 in 5 adults in the United States are either current or former smokers and remain at risk for the development of chronic lung diseases. It is unknown how or why any one individual smoker can develop a wide range of lung diseases including chronic obstructive lung disease and/or pulmonary fibrosis. The purpose of this protocol is to collect clinical data, blood, urine, and bronchoalveolar samples from smokers and non-smokers in an attempt to establish phenotypic clinical profiles that correspond to divergent pathways in the expression of such proteins as the transforming growth factor-beta1 (TGF-beta \<=1). The information generated from this study will provide insight into the pathogenesis of smoking-related lung injury and potentially allow for the development of early therapeutic interventions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the Causes and Disease Processes of Chronic Lung Disease

NCT00001183

Pulmonary Disease

COMPLETED

Evaluation and Treatment of Patients With Lung Disease Not Participating in Research

NCT00001621

Pulmonary Disease

COMPLETED

Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis

NCT02315586

Idiopathic Pulmonary Fibrosis

COMPLETED

Race, Ethnicity, and Diffuse Parenchymal Lung Disease

NCT00453713

Idiopathic Pulmonary Fibrosis Interstitial Lung Disease Diffuse Parenchymal Lung Disease

COMPLETED

Analyzing Lung Tissue in People With and Without Chronic Obstructive Pulmonary Disease Who Are Undergoing Lung Transplantation

NCT00756522

Pulmonary Disease, Chronic Obstructive

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Despite the implementation of modern public health interventions, 1 in 5 adults in the United States are either current or former smokers and remain at risk for the development of chronic lung diseases. It is unknown how or why any one individual smoker can develop a wide range of lung diseases including chronic obstructive lung disease and/or pulmonary fibrosis. The purpose of this protocol is to collect clinical data, blood, urine, and bronchoalveolar samples from smokers and non-smokers in an attempt to establish phenotypic clinical profiles that correspond to divergent pathways in the expression of such proteins as the transforming growth factor-beta1 (TGF-beta1). The information generated from this study will provide insight into the pathogenesis of smoking-related lung injury and potentially allow for the development of early therapeutic interventions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Fibrosis Lung Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lung disease (IPF) and smoking history

50 IPF and 50 COPD patients, and 30 subjects with early interstitial lung abnormalities seen on previous radiographs

No interventions assigned to this group

Lung disease COPD and smoking history

50 IPF and 50 COPD patients, and 30 subjects with early interstitial lung abnormalities seen on previous radiographs

No interventions assigned to this group

Normal Volunteers- Non-smokers, and Smokers

50 smoking and 30 non-smoking controls

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women age 40-80 years
* Smokers with greater than or equal to 10 pack-year history of ever-smoking

* Men and women age 40-80 years
* No prior history of smoking (this is a non-smoking cohort)

For Smoking Controls

* Men and women age 40-80 years
* Subjects who have a prior smoking history

Exclusion Criteria

Subjects will be excluded from the study if they meet one or more of the following criteria:

* Subjects who are under the age of 40 or over 80 years old
* Women who are pregnant or lactating
* Have known allergies to lidocaine or medications used for moderate sedation
* Active coronary artery disease
* Cerebral-vascular accident within the past 12 months
* Active anticoagulation
* Active infections
* Cancer, or a history of cancer within the previous 5 years of screening (other than adequately treated cutaneous basal cell, squamous cell carcinoma, excised melanoma, or carcinoma in situ of the uterine cervix with no evidence of recurrence).
* Poorly controlled chronic diseases
* Unable to provide consent
* Impaired renal function (including dialysis)
* Contraindications to MRI scan including:

* electrical implants such as cardiac pacemakers or perfusion pumps
* ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants
* ferromagnetic objects such as jewelry or metal clips in clothing
* pre-existing medical conditions, including a likelihood of developing seizures or anxiety disorders such as claustrophobia, panic attacks or any psychiatric disorder

* Subjects who are under the age of 40 or over 80 years old
* Women who are pregnant or lactating
* Have known allergies to lidocaine or medications used for moderate sedation
* Active coronary artery disease
* Cerebral-vascular accident within the past 12 months
* Active anticoagulation
* Active infections
* Cancer, or a history of cancer within the previous 5 years of screening (other than adequately treated cutaneous basal cell, squamous cell carcinoma, excised melanoma, or carcinoma in situ of the uterine cervix with no evidence of recurrence).
* Poorly controlled chronic diseases
* Unable to provide consent
* Impaired renal function (including dialysis)
* Contraindications to MRI scan including:

* electrical implants such as cardiac pacemakers or perfusion pumps
* ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants
* ferromagnetic objects such as jewelry or metal clips in clothing
* pre-existing medical conditions, including a likelihood of developing seizures or anxiety disorders such as claustrophobia, panic attacks or any psychiatric disorder

For Smoking Controls

* Subjects who are under the age of 40 or over 80 years old
* Women who are pregnant or lactating
* Have known allergies to lidocaine or medications used for moderate sedation
* Active coronary artery disease
* Cerebral-vascular accident within the past 12 months
* Active anticoagulation
* Active infections
* Cancer, or a history of cancer within the previous 5 years of screening (other than adequately treated cutaneous basal cell, squamous cell carcinoma, excised melanoma, or carcinoma in situ of the uterine cervix with no evidence of recurrence).
* Poorly controlled chronic diseases
* Unable to provide consent
* Impaired renal function (including dialysis)
* Contraindications to MRI scan including:

* electrical implants such as cardiac pacemakers or perfusion pumps
* ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants
* ferromagnetic objects such as jewelry or metal clips in clothing
* pre-existing medical conditions, including a likelihood of developing seizures or anxiety disorders such as claustrophobia, panic attacks or any psychiatric disorder

Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No